Literature DB >> 29191971

Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1.

Guang Peng1, Gordon B Mills2.   

Abstract

Detailed clinical and molecular evaluation of large cohorts of exceptional survivors provides an unprecedented opportunity to identify mechanisms underlying long-term survival that can drive future therapeutic approaches and biomarker development. Exceptional survivors of high-grade serous ovarian cancer demonstrate concurrent disruption of homologous recombination DNA repair and retinoblastoma protein. Clin Cancer Res; 24(3); 508-10. ©2017 AACRSee related article by Garsed et al., p. 569. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29191971      PMCID： PMC5905329          DOI： 10.1158/1078-0432.CCR-17-3022

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

Review 1.  The DNA damage response: putting checkpoints in perspective.

Authors:  B B Zhou; S J Elledge
Journal:  Nature       Date:  2000-11-23       Impact factor: 49.962

2.  DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy.

Authors:  Sean P Pitroda; Itai M Pashtan; Hillary L Logan; Brian Budke; Thomas E Darga; Ralph R Weichselbaum; Philip P Connell
Journal:  Sci Transl Med       Date:  2014-03-26       Impact factor: 17.956

3.  Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.

Authors:  Dale W Garsed; Kathryn Alsop; David D L Bowtell; Anna deFazio; Sian Fereday; Catherine Emmanuel; Catherine J Kennedy; Dariush Etemadmoghadam; Bo Gao; Val Gebski; Valérie Garès; Elizabeth L Christie; Maartje C A Wouters; Katy Milne; Joshy George; Ann-Marie Patch; Jason Li; Gisela Mir Arnau; Timothy Semple; Sreeja R Gadipally; Yoke-Eng Chiew; Joy Hendley; Thomas Mikeska; Giada V Zapparoli; Kaushalya Amarasinghe; Sean M Grimmond; John V Pearson; Nicola Waddell; Jillian Hung; Colin J R Stewart; Raghwa Sharma; Prue E Allan; Peter F Rambau; Orla McNally; Linda Mileshkin; Anne Hamilton; Sumitra Ananda; Marisa Grossi; Paul A Cohen; Yee C Leung; Robert M Rome; Philip Beale; Penny Blomfield; Michael Friedlander; Alison Brand; Alexander Dobrovic; Martin Köbel; Paul Harnett; Brad H Nelson
Journal:  Clin Cancer Res       Date:  2017-10-23       Impact factor: 12.531

Review 4.  Replication stress and cancer.

Authors:  Hélène Gaillard; Tatiana García-Muse; Andrés Aguilera
Journal:  Nat Rev Cancer       Date:  2015-05       Impact factor: 60.716

5.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.

Authors:  V Abkevich; K M Timms; B T Hennessy; J Potter; M S Carey; L A Meyer; K Smith-McCune; R Broaddus; K H Lu; J Chen; T V Tran; D Williams; D Iliev; S Jammulapati; L M FitzGerald; T Krivak; J A DeLoia; A Gutin; G B Mills; J S Lanchbury
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

6.  CDK4/6 inhibition triggers anti-tumour immunity.

Authors:  Shom Goel; Molly J DeCristo; April C Watt; Haley BrinJones; Jaclyn Sceneay; Ben B Li; Naveed Khan; Jessalyn M Ubellacker; Shaozhen Xie; Otto Metzger-Filho; Jeremy Hoog; Matthew J Ellis; Cynthia X Ma; Susanne Ramm; Ian E Krop; Eric P Winer; Thomas M Roberts; Hye-Jung Kim; Sandra S McAllister; Jean J Zhao
Journal:  Nature       Date:  2017-08-16       Impact factor: 49.962

7.  Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.

Authors:  Eileen E Parkes; Steven M Walker; Laura E Taggart; Nuala McCabe; Laura A Knight; Richard Wilkinson; Karen D McCloskey; Niamh E Buckley; Kienan I Savage; Manuel Salto-Tellez; Stephen McQuaid; Mary T Harte; Paul B Mullan; D Paul Harkin; Richard D Kennedy
Journal:  J Natl Cancer Inst       Date:  2016-10-05       Impact factor: 13.506

8.  Deciphering signatures of mutational processes operative in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Peter J Campbell; Michael R Stratton
Journal:  Cell Rep       Date:  2013-01-10       Impact factor: 9.423

9.  Signatures of mutational processes in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962

10.  Genome-wide transcriptome profiling of homologous recombination DNA repair.

Authors:  Guang Peng; Curtis Chun-Jen Lin; Wei Mo; Hui Dai; Yun-Yong Park; Soo Mi Kim; Yang Peng; Qianxing Mo; Stefan Siwko; Ruozhen Hu; Ju-Seog Lee; Bryan Hennessy; Samir Hanash; Gordon B Mills; Shiaw-Yih Lin
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919
View more
  6 in total

Review 1.  Proteomics advances for precision therapy in ovarian cancer.

Authors:  Marilyne Labrie; Nicholas D Kendsersky; Hongli Ma; Lydia Campbell; Jennifer Eng; Koei Chin; Gordon B Mills
Journal:  Expert Rev Proteomics       Date:  2019-09-13       Impact factor: 3.940

2.  Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer.

Authors:  Xi Zhang; Weikaixin Kong; Miaomiao Gao; Weiran Huang; Chao Peng; Zhuo Huang; Zhengwei Xie; Hongyan Guo
Journal:  J Cell Mol Med       Date:  2022-06-23       Impact factor: 5.295

3.  RB1 Is an Immune-Related Prognostic Biomarker for Ovarian Cancer.

Authors:  Biao Xie; Guangqing Tan; Jingyi Ren; Weiyu Lu; Sadaf Pervaz; Xinyi Ren; Antonia Adwoa Otoo; Jing Tang; Fangfang Li; Yingxiong Wang; Meijiao Wang
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

4.  A novel ferroptosis related gene signature is associated with prognosis in patients with ovarian serous cystadenocarcinoma.

Authors:  Zhixiang Yu; Haiyan He; Yanan Chen; Qiuhe Ji; Min Sun
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

5.  The role of RB1 alteration and 4q12 amplification in IDH-WT glioblastoma.

Authors:  Antonio Dono; Arvind V Ramesh; Emily Wang; Mauli Shah; Nitin Tandon; Leomar Y Ballester; Yoshua Esquenazi
Journal:  Neurooncol Adv       Date:  2021-03-31

6.  miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling.

Authors:  Matthew Knarr; Rita A Avelar; Sreeja C Sekhar; Lily J Kwiatkowski; Michele L Dziubinski; Jessica McAnulty; Stephanie Skala; Stefanie Avril; Ronny Drapkin; Analisa DiFeo
Journal:  Nat Commun       Date:  2020-06-26       Impact factor: 17.694
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.